Insitu Biologics: Funding, Investors & Team (Sep 2026)
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
Insitu Biologics has raised $5.3M across 2 funding rounds on record, the most recent a Convertible Note of $1.3M announced in Aug 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Insitu Biologics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Insitu Biologics Funding Rounds
Insitu Biologics raised $4.0M in an undisclosed round announced in Dec 2025.
8 months later, a Convertible Note of $1.3M was announced in Aug 2026.
Insitu Biologics Investors
Insitu Biologics Founders and Leadership Team
Contact details for the Insitu Biologics team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Insitu Biologics Funding Compared to Other Biotechnology Startups
Insitu Biologics' latest round of $1.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Insitu Biologics in Biotechnology and Minnesota City
Companies Similar to Insitu Biologics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Insitu Biologics Funding FAQs
What does Insitu Biologics do?
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
How much funding has Insitu Biologics raised?
Insitu Biologics has raised $5.3M across 2 rounds on record. The most recent is a Convertible Note of $1.3M announced in Aug 2026.
When did Insitu Biologics last raise funding?
Insitu Biologics' most recent funding round on record is a Convertible Note of $1.3M, announced in Aug 2026.
Who has invested in Insitu Biologics?
Investors on record for Insitu Biologics include Manhattan Street Fund.
Who founded Insitu Biologics?
FundedIQ lists Bill Taylor (Founder) at Insitu Biologics.
Who is the CEO of Insitu Biologics?
Dan Halpern is listed as CEO at Insitu Biologics.
Where is Insitu Biologics headquartered?
Insitu Biologics is based in Minnesota City, Minnesota, United States.
How many employees does Insitu Biologics have?
Insitu Biologics is in the 11-50 employee band.
When was Insitu Biologics founded?
Insitu Biologics was founded in 2014.
How does Insitu Biologics' funding compare to other Biotechnology startups?
Insitu Biologics' latest round of $1.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Insitu Biologics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Insitu Biologics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.